Highest-materiality recent filing
Coherus Q1 LOQTORZI rev $11.8M (+61% YoY); net loss $36.9M; pipeline readouts mid-2026
LOQTORZI net revenue $11.8M in Q1 2026, up 61% YoY from $7.3M but down 5% from Q4 2025 $12.4M due to weather and seasonality.
Coherus Oncology reports FY2025 net loss $183.1M; LOQTORZI revenue doubles to $40.8M
LOQTORZI net revenue $40.8M in 2025, more than double $19.1M in 2024; Q4 net revenue $12.4M up 11% QoQ.
Coherus Oncology closes $47M public offering of 28.6M shares at $1.75/share
Issued 28.6M common shares at $1.75 public price; underwriters paid $1.645/share.
Coherus enters Phase 1b combo trial with Janssen for tagmokitug in mCRPC
Clinical supply agreement with Janssen to evaluate tagmokitug (anti-CCR8) plus pasritamig in mCRPC Phase 1b.
Coherus Oncology files prospectus supplement for $64.9M ATM stock offering
Aggregate offering price of up to $64,880,054 under Sales Agreement with TD Cowen.
Coherus recasts FY 2024/2023 financials for UDENYCA divestiture as discontinued operations
UDENYCA sale to Intas completed April 11, 2025 for $483.4M upfront cash including $118.4M inventory.
Net revenue $11.6M (up 90% YoY); LOQTORZI net revenue $11.2M (+12% QoQ, +92% YoY).
Coherus Oncology regains Nasdaq compliance after bid price shortfall
On June 30, 2025, Coherus received a Nasdaq deficiency notice for bid price below $1.00 for 30 consecutive business days.
Coherus Q2 LOQTORZI rev $10M (+36% QoQ); UDENYCA divestiture closed for $483M
LOQTORZI net revenue $10.0M in Q2 2025, up 36% from $7.3M in Q1 2025 and $3.8M in Q2 2024.
Coherus Oncology receives Nasdaq bid price deficiency notice; 180 days to regain compliance
On June 30, 2025, Nasdaq notified Coherus that its common stock closed below $1.00 for 30 consecutive business days.
Coherus Q1 2025: LOQTORZI rev $7.3M, net loss $47.4M; UDENYCA divestiture closed
Continuing ops net loss $47.4M ($0.41 diluted); non-GAAP net loss $40.9M ($0.35).
Coherus completes UDENYCA divestiture to Intas for $483.4M upfront; pivots to oncology
Closed sale of UDENYCA franchise on April 11, 2025; receives $483.4M cash including $118.4M for inventory.
Coherus to repurchase $170M of convertible notes, conditional on UDENYCA sale close
Coherus agreed to repurchase ~$170M aggregate principal of its 1.500% Convertible Notes due 2026 at 100% par plus accrued interest.
Coherus stockholders approve UDENYCA sale to Intas Pharmaceuticals
Stockholders voted 70,989,067 FOR, 968,989 AGAINST, 621,431 ABSTAIN; majority threshold was 57,945,094.
Coherus swings to FY 2024 net income of $28.5M; UDENYCA divestiture on track
FY 2024 net income $28.5M ($0.25 diluted EPS) vs net loss $237.9M in FY 2023; revenue $267M, +4%.
Coherus supplements proxy for UDENYCA sale; discloses JPMorgan valuation & cash flow projections
Four shareholder complaints filed in NYC Supreme Court alleging proxy deficiencies; company denies merit.
Coherus to divest UDENYCA franchise to Intas for up to $558.4M; plans to repay convertible notes
Upfront cash $483.4M (subject to inventory adj.) plus up to $75M in net sales milestones ($37.5M each at $300M and $350M thresholds).
Coherus Q3 revenue $70.8M, UDENYCA up 30% QoQ; net loss narrows to $10.8M from $39.6M YoY
Net revenue $70.8M; UDENYCA $66.1M (+30% QoQ, +100% YoY); LOQTORZI $5.8M (+54% QoQ).
Coherus warns of temporary UDENYCA supply interruption due to packaging CMO constraints
Third-party CMO over-commitments cause labeling/packaging delay; API and drug product unaffected.
Coherus Q2 net loss narrows to $12.9M; UDENYCA sales up 60% YoY; appoints new CFO
Q2 2024 net revenue $65.0M (+11% YoY); net loss $12.9M ($0.11 loss per share) vs $42.9M loss in Q2 2023.
Coherus sells YUSIMRY (adalimumab-aqvh) to HKF for $40M upfront cash
Upfront all-cash consideration of $40M; closing occurred June 26, 2024.
Coherus discloses terms of senior secured term loan and revenue participation sale
Filed Loan Agreement: senior secured term loan from multiple lenders, interest at Term SOFR + margin, maturity date TBD.
Coherus enters $38.7M term loan and $37.5M royalty sale to repay $75M prior debt
New $38.7M senior secured term loan at 8.00% + 3M SOFR; matures May 8, 2029; interest-only quarterly.
Coherus Q1 revenue $77.1M, net income $102.9M; UDENYCA +63% YoY; LOQTORZI launch underway
Net revenue $77.1M in Q1 2024 vs $32.4M in Q1 2023; GAAP net income $102.9M ($0.83 diluted EPS) vs net loss of $75.7M.
Coherus reports FY2023 revenue $257.2M, divests CIMERLI to Sandoz for $170M, plans debt paydown
Q4 2023 net revenue $91.5M (+102% YoY); FY2023 $257.2M (+22% YoY); net loss $79.7M Q4, $237.9M FY.
Coherus completes CIMERLI ophthalmology sale to Sandoz for $170M cash; repays $175M debt
Closed sale of CIMERLI franchise to Sandoz for upfront $170M cash plus $17.8M for inventory and prepaid manufacturing assets.
Coherus amends loan with Pharmakon; to prepay $175M, reduce interest ~70%
After closing ophthalmology divestiture to Sandoz, Coherus will prepay $175M of $250M loan principal, leaving $75M residual.
Coherus divests CIMERLI ophthalmology franchise to Sandoz for $170M upfront cash
Divestiture of CIMERLI (ranibizumab-eqrn) and supporting commercial infrastructure to Sandoz.
Coherus receives FDA approval for UDENYCA ONBODY on-body injector
FDA approved UDENYCA ONBODY on December 26, 2023, a pegfilgrastim biosimilar to reduce febrile neutropenia after chemotherapy.
Coherus sets LOQTORZI price at $8,892.03/vial for NPC treatment
FDA approved LOQTORZI (toripalimab-tpzi) on Oct 27 for first-line and later-line metastatic NPC.
Coherus files Surface Oncology audited financials: $63.6M net loss in 2022, going concern noted
Surface Oncology reported net loss of $63.6M for 2022 on $30M revenue; accumulated deficit reached $204.3M.
Coherus Q3 net revenue $74.6M (+27% QoQ); net loss narrows to $39.6M; LOQTORZI approved
Q3 2023 net revenue $74.6M, up 27% from Q2; net loss $39.6M ($0.41/sh) vs $86.7M ($1.11/sh) in Q3 2022.
On April 22, 2025, Mark D. Stolper, a member of the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), notified the Board of his intention not to stand for re-election to the Board for an additional three-year term at the Company's 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).
Paul Reider notified Coherus BioSciences, Inc. (the “Company”) on April 16, 2025 of his resignation as Chief Commercial Officer and employee of the Company effective on April 30, 2025 in order to pursue other opportunities
On August 7, 2024, the Company’s board of directors appointed Bryan McMichael, age 46, the Company’s current Interim Chief Financial Officer, Executive Vice President, Accounting, Corporate Controller, to serve as the Company’s Chief Financial Officer effective August 1, 2024.
the vacancy on the Board created by such increase would be filled by the appointment of Rita A. Karachun, with such appointment becoming effective upon the receipt of certain confirmations, which were received May 31, 2024.
On February 20, 2024, the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), increased the size of the Board from nine directors to ten directors and approved, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the appointment of Georgia Erbez to serve as a Class III director to fill the vacancy created by such increase.
The Board of Directors of the Company appointed Bryan McMichael, age 45, to serve as the Company’s Interim Chief Financial Officer and Principal Financial Officer effective December 8, 2023.
McDavid Stilwell notified the Company on December 7, 2023 of his resignation as Chief Financial Officer, Principal Financial Officer and employee of the Company in order to pursue other opportunities, in each case to be effective on December 31, 2023.
McDavid Stilwell notified the Company on December 7, 2023 of his resignation as Chief Financial Officer, Principal Financial Officer and employee of the Company in order to pursue other opportunities, in each case to be effective on December 31, 2023.
On July 18, 2023, the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), approved, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the appointment of Michael Ryan, Pharm.D., to serve as a Class III director to fill a vacancy on the Board.
On March 2, 2023, Vladimir Vexler, Ph.D., resigned from his role as Chief Scientific Officer of the Company, effective March 10, 2023, unless the effective date is extended to March 31, 2023 at Dr. Vexler’s option.
On September 9, 2022, Coherus BioSciences, Inc. (the “Company”) announced the appointment of Bryan McMichael, age 44, as Senior Vice President, Accounting, Corporate Controller and Principal Accounting Officer, effective September 7, 2022.
Mr. Stilwell continues his service to the Company as the Company’s Chief Financial Officer and Principal Financial Officer but will no longer serve as Principal Accounting Officer effective September 7, 2022.
Max materiality 0.85 · Median 0.65 · Most common event other_material